DeCure for Acinar Prostate Mucinous Adenocarcinoma
DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Acinar Prostate Mucinous Adenocarcinoma — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAcinar Prostate Mucinous Adenocarcinoma maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for acinar prostate mucinous adenocarcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ETS transcription factor ERG (ERG) — ERG is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet qwpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6VGG · 4.31 Å · ligand mithramycin (QWP). Experimental structure, not a prediction.
What the evidence adds up to
In a CaPSURE registry analysis of 151 men with clinical T3 or T4 prostate adenocarcinoma who completed baseline and at least two years of follow-up, mean urinary function scores fell from 91 at baseline to 82, 83 and 82 at one, two and three years after treatment. Mean sexual function scores dropped from 38 at baseline to 15, 16 and 14 at the same intervals. Treatment types included radical prostatectomy (21%), cryotherapy (8%), brachytherapy (17%) and hormonal ablation (54%). Quality of life varied significantly by treatment type on multivariate analysis. The abstract does not specify how many of these men had mucinous histology.
A 1986 review of 30 published cases plus one new case of mucinous adenocarcinoma of the prostate reported that the tumour was positive for prostate specific antigen by immunohistochemistry. The authors stated that earlier claims that mucinous adenocarcinoma is insensitive to hormonal therapy, rarely produces acid phosphatase and rarely metastasises to bone were not supported by their case or by the frequent presence of coexisting acinar elements. They concluded there was no significant difference in clinical behaviour between mucinous and ordinary acinar carcinomas.
A 2014 case report described a 68-year-old man with metastatic mucinous adenocarcinoma of the prostate treated with radical prostatectomy, radiotherapy and androgen deprivation. The authors noted an excellent clinical course and stated that in their case the tumour did not appear to behave differently from acinar prostate cancer, with malignant potential dependent on Gleason score. A 2010 case report described a 59-year-old man with advanced mucinous prostatic adenocarcinoma involving almost the entire bladder who had failed hormonal treatment and radiotherapy but underwent radical pelvic exenteration surgery. He remained alive with undetectable PSA and no evidence of recurrence on surveillance CT scans 11 years after surgery.
A 2023 immunohistochemical study of 82 primary prostatic adenocarcinoma specimens examined expression of ATRX, androgen receptor and EGFR. AR-positive/high and preserved ATRX expression were significantly linked to low pT stage, low-grade group and absence of lymph node invasion. EGFR high expression was significantly related to high-grade group and presence of lymph node invasion. Loss of ATRX expression correlated significantly with AR-negative/low status, high EGFR expression and adverse clinicopathological factors. The study did not separate mucinous from acinar cases.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The Journal of Urology · 2008 · 22 citations
Quality of Life in Men With Locally Advanced Adenocarcinoma of the Prostate: An Exploratory Analysis Using Data From the CaPSURE Database
AbstractPURPOSE: We present longitudinal quality of life outcomes in a national observational cohort of men with locally advanced prostate adenocarcinoma. MATERIALS AND METHODS: The CaPSURE registry was used to evaluate quality of life in men with clinical T3 or T4 prostate adenocarcinoma who underwent primary treatment and had a minimum followup of 2 years. Records were reviewed for treatment, patient age, T stage, prostate specific antigen at diagnosis, body mass index, and initial and posttreatment quality of life using the SF-36 and UCLA-PCI questionnaires, which can each be scored from 0 to 100 with higher scores indicating better outcomes. The association of treatment type and quality of life changes after treatment were evaluated with multivariate mixed model analysis, adjusting for age, time of quality of life assessment, and interaction between treatment and time. RESULTS: Of the 13,740 men enrolled in CaPSURE 608 (4.42%) presented with T3 or T4 tumors. In this subgroup 151 men completed baseline and a minimum of 2 years of followup with quality of life data available. These men underwent primary treatment with radical prostatectomy (21%), cryotherapy (8%), brachytherapy (17%) or hormonal ablation (54%). The treatment cohort demonstrated significant decreases in quality of life, most profoundly in urinary and sexual function. Mean urinary function was 91 at baseline, which decreased to 82, 83 and 82 at 1, 2 and 3 years after treatment, respectively (p = 0.04). Mean sexual function was 38 at baseline, which decreased to 15, 16 and 14 at 1, 2 and 3 years after treatment, respectively (p <0.01). On multivariate analysis quality of life varied significantly by treatment type (p <0.01). CONCLUSIONS: Treatment for locally advanced prostate adenocarcinoma is associated with a significant burden in patients, notably decrements in urinary and sexual function. Clinicians should consider the impact that treatment imparts on quality of life when counseling patients with locally advanced disease.
Mucinous Adenocarcinoma of Prostate: A Case Report and Review of the Literature
AbstractMucinous adenocarcinoma of the prostate is rare and its biological behavior is not well known. We report a case of mucinous adenocarcinoma of the prostate, which was treated successfully with castration. Positivity for prostatic specific antigen by immunohistochemistry confirmed the prostatic origin of this tumor. A review of the literature revealed 30 authentic cases. Prostatic mucinous adenocarcinoma has been said to be different clinically from ordinary prostatic adenocarcinoma. It is insensitive to hormonal therapy, rarely produces acid phosphatase and rarely metastasizes to the bone. However, our case, together with the frequent presence of coexisting acinar elements in mucinous adenocarcinoma, indicates no significant difference in the clinical behavior between mucinous and ordinary acinar carcinomas.
Case Reports in Urology · 2014 · 3 citations · open access
Metastatic Mucinous Adenocarcinoma of the Prostate with PSA Value of 8.6 ng/mL at 5-Year-Followup after Prostatectomy, Radiotherapy, and Androgen Deprivation
AbstractIntroduction. Mucinous adenocarcinoma of the prostate is a rare variant of prostate cancer. Its malignant potential and the clinical course of the affected patients remain, by and large, controversial. No data exist about the course of metastatic mucinous adenocarcinoma of the prostate. Case Presentation. This case report describes the excellent clinical course of a 68-year-old patient with metastatic mucinous adenocarcinoma of the prostate, treated by radical prostatectomy, irradiation, and androgen deprivation. Conclusion. In our case, mucinous adenocarcinoma of the prostate does not appear to behave differently than acinar prostate cancer. Its malignant potential is dependent on its Gleason score.
Journal of Surgical Case Reports · 2010 · 0 citations · open access
Radical exenteration surgery is curative in locally advance mucinous prostatic adenocarcinoma involving bladder and rectum
AbstractThe management of mucinous prostatic adenocarcinoma include hormonal treatment, radiotherapy and radical prostatectomy with variable long-term outcome. We report a 59 year old man with advanced mucinous prostatic adenocarcinoma involving almost the entire bladder and had failed treatment with hormonal and radiotherapy, but subsequently underwent radical pelvic exenteration surgery that resulted in long-term cure. He remains alive, his PSA remains undetectable and his surveillance CT scans did not show any evidence of recurrence after 11 years post-surgery. The favourable outcome of radical surgery suggests that radical surgery should be considered, especially in cases with failed initial treatments.
Journal of Microscopy and Ultrastructure · 2023 · 0 citations · open access
Alpha Thalassemia/Intellectual Disability Syndrome X-Linked Expression Varies Significantly between Androgen Receptor-Positive and Androgen Receptor-Negative Prostatic Adenocarcinoma: Relation to Epidermal Growth Factor Receptor Expression and Clinicopathological Factors
AbstractAbstract Background: Prostate cancer (PC) is the most common cancer and a leading cause of cancer-related mortality in men worldwide. It has become clear that signaling pathways that are implicated in prostatic carcinoma (PCa) initiation and propagation evolved through interactions of several factors. Alpha Thalassemia/Intellectual Disability syndrome X-linked (ATRX) is a chromatin remodeling protein that has an essential role in telomere stability. The androgen receptor (AR) and growth factors especially the epidermal growth factor receptor (EGFR) seem not to function independently in PCa proliferation. This work aimed to study the expression of ATRX in primary prostatic adenocarcinoma in relation to AR and EGFR expression and the significance of biomarkers expression to the known clinicopathological factors. Materials and Methods: Eighty-two primary prostatic adenocarcinoma paraffin blocks were stained immunohistochemically with AR, ATRX, and EGFR polyclonal antibodies. PCa was divided into AR +/hi and AR −/lo depending on the percentage and intensity of stained cells regardless of AR heterogeneity. ATRX immunostaining was categorized into ATRX preserved expression or ATRX loss. EGFR expression was grouped into low and high expression according to the staining percentage and intensity. Results: AR +/hi and preserved ATRX expression significantly were linked to low pT stage, low-grade group, and absence of lymph node invasion. While significant EGFR high expression was related to the high-grade group and the presence of lymph node invasion. Conclusion: ATRX preserved expression varies significantly between AR +/hi and AR −/lo PCa which is related to favorable clinicopathological factors. However, the loss of ATRX expression correlated significantly with AR −/low , high EGFR expression, and adverse clinicopathological factors.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
